Costanza Bosi

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Haematologica · 2007 · 190 citations · Full text

Medicine, Oncology, Pharmacology +11

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 149 citations · Full text

Medicine, Hematology, Pharmacology +10

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

Matilde Y. Follo, Carlo Finelli, Sara Mongiorgi et al. · Proceedings of the National Academy of Sciences · 2009 · 121 citations · Full text

Medicine, Oncology, Pharmacology +16

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

Maria Nyåkern, Pier Luigi Tazzari, Carlo Finelli et al. · Leukemia · 2005 · 101 citations

Medicine, Hematology, Molecular Medicine +12

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Francesca Palandri, Giuseppe A. Palumbo, Massimiliano Bonifacio et al. · Oncotarget · 2017 · 91 citations · Full text

Medicine, Hematology, Pharmacology +10